T
Taj For DoctorsTaj Doctor
home

About Us

Taj Brands

Diseases Health Tips  HIV/AIDS News Contact Us

 

  All News
  Allergy
  Asthma
  Cardiology
  Clinical Research
  Critical Care
  Dentistry
  Dermatology
  Endocrinology
  Gastroenterology
  General
  Genetics / Biotech
  Men's Health
  Infectious Diseases
  Fitness/Lifestyle
  Nephrology
  Neurology
  Oncology/Haematology
  Ophthalmology
  Orthopaedics
  Otolaryngology
  Paediatrics
  Psychiatry
  Reproductive Health
  Respiratory Medicine
  Surgery
  Sex
  Urology
  Women's Health
Taj Brands


Therapeutic Index

REXIPRO

    Each Vial 5ml contains:

 

     Composition:

     Abciximab .....................................................................2 mg

 

    Indications :

   Platelet aggregation inhibition as adjunct to percutaneous   

     transluminal coronary angioplasty or atherectomy (PTCA).

 
   
Description:

    Abciximab (c7E3) is a chimeric mouse-human monoclonal

   antibody directed against the GP IIb/IIIa receptor; its mechanism of

   action is thought to be steric hindrance of the receptor itself as

    opposed to direct binding to the RGD binding site of the receptor. It also inhibits the vitronectin (av b3)receptor, which mediates both

   platelet coagulation as well as endothelial and vascular smooth

    muscle cell proliferation.

 

     Dosage: 0.25 mg/kg administered 10-60 minutes before the start

    of PTCA ` followed by a continuous I.V.. Injection of 10 mcg/min.

     for 12 hours.

 

     Presentations:        Vial 5ml

                                    MRP            Retailer           Stockiest

                                19740.00      15792.00          14212.80

 
 
 

         Copyright 2004- 2006 TAJ Pharmaceuticals Limited. All Rights Reserved.

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274 

Terms and Conditions | Disclaimer | Privacy Policy | Sitemap | Feedback | FAQ